When people talk about lowering cholesterol, statins get most of the attention. But there is a second family of lipid-lowering drugs that does the quiet, heavy lifting for millions of patients with stubborn triglyceride problems: the fibrates. Inside that family, one molecule dominates the field. Fenofibrate is the most prescribed fibrate in the world. It did not land as some sudden breakthrough. It grew out of a slow, stubborn effort to rescue a drug that had already fallen from grace. This is the story of how a French lab reshaped a discredited molecule into a global standard, and why it still matters for patients today. The fog around cholesterol The…